Login
$QNRX
$3.69 -$0.01 (0.27%) Live

$QNRX SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
12 Nov 2026 8-K: Submission of Matters to a Vote of Security Holders

Quoin Pharmaceuticals Ltd. (“we,” “us,” or the “Company”) held a Special General Meeting of Shareholders (the “Special Meeting”) on November 12, 2026. During the Special Meeting, shareholders were asked to consider and vote upon two prop...

06 Nov 2026 8-K: Results of Operations and Financial Condition

– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target

05 Nov 2026 10-Q
04 Nov 2026 EFFECT
04 Nov 2026 8-K: Entry into a Material Definitive Agreement

Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:

04 Nov 2026 424B5
04 Nov 2026 424B5
28 Oct 2026 FORM S-3
26 Oct 2026 Form 4/A: Langer Dennis, Director

Holds 49,687 shares of ADSs

20 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

14 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

07 Oct 2026 SCHEDULE 13G/A
02 Oct 2026 DEF 14A
25 Sep 2026 EFFECT
25 Sep 2026 424B3
22 Sep 2026 PRE 14A
22 Sep 2026 8-K: Regulation FD Disclosure; Other Events

First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy

18 Sep 2026 FORM S-3
10 Sep 2026 D

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support